News

Natus Medical has reported revenue of $37.3 million for the second quarter ended June 30, 2009, a decrease in comparison to $39.9 million in the second quarter of

Lundbeck has announced the joint decision with its partner, Solvay to stop all joint R&D activities for Solvay’s compound – bifeprunox in development phase. The compound is intended

Vertex and Mitsubishi Tanabe Pharma have amended their agreement for the development and commercialization of telaprevir (for the treatment of hepatitis C virus (HCV) infection) in Japan and

BioMarin has reported that the US Patent Office has issued patents covering stable tablet formulation and the approved once daily dosing regimen for Kuvan, for the treatment of

AstraZeneca has submitted a New Drug Application to the FDA, and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for an investigational drug – vandetanib

Obagi has reported positive results of 12-week study comparing CLENZIderm Serum Gel to a combination prescription benzoyl peroxide (BPO)/clindamycin product.   In this multicenter, investigator-blind, randomized, split-face study,

Debiopharm and MSM Protein (MSM) have sealed an agreement for the development and commercialisation of Debio 0929, to be developed into a new oncology therapeutic drug. Debio 0929

Thoratec and HeartWare International are disappointed with the FTC’s decision to challenge the acquisition. The companies intend to review the FTC’s decision and mutually assess the appropriate next

The Dow Chemical Company and Petroliam Nasional Berhad (PETRONAS) have reached an agreement for Dow’s Union Carbide Corporation subsidiary, to sell its entire shares of ownership in the